Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 835 results for "sun pharma advanced research"

SPARC, Sun Pharma in focus
India Infoline

SPARC licenses glaucoma medicine, Xelpros to Sun Pharma

Sun Pharma Advanced Research Company Ltd. (SPARC) has licensed out Xelpros (latanoprost BAK-free eye drops) to a subsidiary of Sun Pharma for the US market. In addition to up-front payment of USD 3 million, SPARC will receive certain other ... PharmaBiz, 2 weeks ago
[x]  

39 images for sun pharma advanced research

India Infoline, 2 weeks ago
India Infoline, 2 weeks ago
India Infoline, 2 weeks ago
Business Today India, 2 weeks ago
India Infoline, 1 month ago
India Infoline, 1 month ago
India Infoline, 3 months ago
Sify, 4 weeks ago
USA.Gov, 1 month ago
International Business Times India, 4 weeks ago

Buy Sun Pharma Advanced Research on dips: Prakash Diwan

"There is nobody who can put a target on this in terms of a PE multiple and valuation. It is into a black box. So, it is best to have it on dips. Buy it every time it gives you some leeway in the correction. What could go wrong is the ownership if ...
 Moneycontrol.com2 weeks ago Sun Pharma Advanced Research Company informs about Press Release  Finalaya.com3 weeks ago SPARC to provide update on NCE NDDS programs  Money Control3 weeks ago Buy Sun Pharma Advanced Research Company: Sudarshan Sukhani  Money Control1 month ago
[x]  
Oneindia

SPARC Rallies 4% On Licensing Xelpros To Sun Pharma

, 12:04 [IST] Shares in Sun Pharma Advanced Research Company (SPARC) rallied 4 per cent after reports that the company had licensed out Xelpros (Latanoprost BAK-free eye drops) to a subsidiary of Sun Pharma for the US market. Sun Pharma ...
 Oneindia2 weeks ago

Sell India Cement with a stop loss of 82, target of 70: Sandeep Wagle, Power My Wealth

'I would go with a sell in a India Cement with a stop loss of 82 and target of 70. A buy in a SPARC (Sun Pharma Advance Research) with a stop loss of 390 and target of 448.' In a chat with ET Now, Sandeep Wagle, Founder & CEO of Power My Wealth, shares his ...
 Economic Times3 weeks ago

Volumes jump at GSK Consumer Healthcare counter

Sun TV Network, Bhushan Steel, Eros International Media and Sun Pharma Advanced Research Company are among the other stocks to see a surge in volumes on BSE today, 8 June 2015. GlaxoSmithkline Consumer Healthcare clocked volume of 31,000 ...
 Capital Market3 weeks ago
Money Control

SPARC to raise funds up to Rs 250 crore through rights issue

Sun Pharma Advanced Research Company (SPARC) has received an approval for further issuance of equity shares of Re 1 each of the company, on rights basis to the shareholders of the company on such ratio and at such price and premium as may be decided ...
 Indian-Commodity1 month ago SPARC to raise Rs 250 crore through rights issue  Business Standard1 month ago

Sun Pharma Advanced Research declines on reporting net loss of Rs 9.40 crore in Q4

SENSEX 26982.56 457.58 1.67% NIFTY 8181.00 143.80 1.73% Industry: Medical/Healthcare Company Sun ...
 Finalaya.com1 month ago Sun Pharma Advanced Research reports net loss of Rs 9.40 crore in Q4  Finalaya.com1 month ago SPARC rises on receiving approval to raise funds up to Rs 250 crore  Finalaya.com1 month ago SPARC in green on receiving approval to raise funds up to Rs 250 crore  Indian-Commodity1 month ago
[x]  
India Infoline

SPARC board meets for rights issue

The Board of Sun Pharma Advanced Research Company will meet on Tuesday to consider an issue of equity shares of ₹1 each by way of a rights issue. The board, however, will not decide on the ratio of rights share entitlements, issue price or record ...
 Hindu Business Line1 month ago Sun Pharma Advanced Board to consider Right Issue  India Infoline1 month ago SPARC board to meet next week to consider fund raising  Business Standard1 month ago SPARC Board to consider Right Issue  India Infoline1 month ago

SPARC jumps on rights issue plan

Sun Pharma Advanced Research Company rose 2.71% to Rs 386.25 at 9:54 IST on BSE after the company said its board will meet on 12 May 2015 to consider rights issue of equity shares. The announcement was made after market hours yesterday, 7 May ...
 Capital Market1 month ago
Moneycontrol.com

Sun Pharma Advance Research net loss rises to Rs.9.40 crore in Q4

Sun Pharma Advanced Research Company (SPARC) has suffered setback during the fourth quarter ended March 2015 and its net loss increased sharply to Rs. 9.40 crore from Rs. 2.51 crore in the corresponding period of last year. The higher loss is due to ...
 PharmaBiz1 month ago SPARC net loss widens to Rs 9.40 crore in Q4  Economic Times1 month ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - sun pharma advanced research
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less